CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide

Last Updated: August 27, 2015
Result type: Reports
Project Number: SR0449-000
Product Line: Reimbursement Review

Generic Name: Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide

Brand Name: Genvoya

Manufacturer: Gilead Sciences Canada, Inc.

Therapeutic Area: HIV infection

Indications: HIV-1 infection

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: March 18, 2016

Recommendation Type: List